Argenx Shares Climb 2.45% Despite 34.15% Volume Drop to 397th Rank as JPMorgan Raises Price Target

On August 4, 2025, Argenx (ARGX) traded with a volume of $0.28 billion, a 34.15% decline from the previous day, ranking 397th in market activity. The stock rose 2.45% to close the session.

JPMorgan raised its price target for Argenx to €730 from €700 while retaining an Overweight rating. The move underscores confidence in the company’s pipeline, including its flagship therapy Vyvgart for autoimmune conditions and recent regulatory approvals for subcutaneous formulations. Argenx’s focus on niche autoimmune diseases positions it as a key player in biotech, with a €41.56 billion market cap.

Financial metrics highlight Argenx’s strength: 66.7% year-over-year revenue growth, 89.43% gross margin, and 42.93% net margin. Liquidity remains robust, with current and quick ratios at 5.6 and 5.27, respectively. However, a Piotroski F-Score of 3 and a Beneish M-Score of -0.24 signal potential operational and financial risks.

Valuation indicators suggest a premium: a P/E ratio of 35.04 and a forward P/E of 54.06 reflect growth expectations. Analysts project a target price of €801.78, though an RSI of 82.41 indicates overbought conditions. Institutional ownership at 54.71% reinforces investor confidence, while a beta of 0.39 highlights lower market sensitivity.

The strategy of purchasing top 500 stocks by daily trading volume and holding for one day returned 166.71% from 2022 to present, outperforming the benchmark by 137.53%. This underscores liquidity concentration’s role in short-term gains, particularly in volatile markets, driven by institutional and algorithmic activity amplifying price movements.